Development of CBT for chemotherapy-related cognitive change: Results of a waitlist control trial

Robert J. Ferguson, Brenna McDonald, Michael A. Rocque, Charlotte T. Furstenberg, Susan Horrigan, Tim A. Ahles, Andrew Saykin

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy of a brief cognitive-behavioral therapy (CBT) that is being developed for management of cognitive dysfunction following chemotherapy among breast cancer survivors. Memory and Attention Adaptation Training (MAAT) is a brief CBT designed to improve the quality of life and function among cancer survivors with post-chemotherapy cognitive complaints. Methods: An initial, two-group (MAAT versus waitlist, no treatment control), randomized clinical trial (RCT) was conducted. Forty stage I and II female breast cancer survivors (mean age = 50; SD = 6.4) were randomized to conditions and assessed at baseline, post-treatment (8 weeks) and 2-month follow-up assessment points on measures of: (1) self-reported daily cognitive failures; (2) quality of life; and (3) neuropsychological performance. Participants were also assessed for satisfaction with MAAT. Results: With education and IQ as covariates, MAAT participants made significant improvements relative to controls on the spiritual well-being subscale of the quality of life measure and on verbal memory, but statistical significance was not achieved on self-report of daily cognitive complaints. However, moderate-to-large effect sizes were observed on these outcomes. Participants gave MAAT high satisfaction ratings. Conclusions: Although this initial RCT is a small study, MAAT participants appear to improve on one measure of quality of life and verbal memory performance relative to no treatment controls and rate MAAT with high satisfaction. These data are encouraging and support the continued development and evaluation of MAAT efficacy.

Original languageEnglish
Pages (from-to)176-186
Number of pages11
JournalPsycho-Oncology
Volume21
Issue number2
DOIs
StatePublished - 2012

Fingerprint

Cognitive Therapy
Drug Therapy
Quality of Life
Survivors
Randomized Controlled Trials
Breast Neoplasms
Self Report
Therapeutics
Education

Keywords

  • breast cancer
  • chemotherapy
  • cognitive dysfunction
  • cognitive-behavioral therapy
  • survivorship

ASJC Scopus subject areas

  • Oncology
  • Psychiatry and Mental health
  • Experimental and Cognitive Psychology

Cite this

Development of CBT for chemotherapy-related cognitive change : Results of a waitlist control trial. / Ferguson, Robert J.; McDonald, Brenna; Rocque, Michael A.; Furstenberg, Charlotte T.; Horrigan, Susan; Ahles, Tim A.; Saykin, Andrew.

In: Psycho-Oncology, Vol. 21, No. 2, 2012, p. 176-186.

Research output: Contribution to journalArticle

Ferguson, Robert J. ; McDonald, Brenna ; Rocque, Michael A. ; Furstenberg, Charlotte T. ; Horrigan, Susan ; Ahles, Tim A. ; Saykin, Andrew. / Development of CBT for chemotherapy-related cognitive change : Results of a waitlist control trial. In: Psycho-Oncology. 2012 ; Vol. 21, No. 2. pp. 176-186.
@article{e702588ac025469bbff493d5b326d323,
title = "Development of CBT for chemotherapy-related cognitive change: Results of a waitlist control trial",
abstract = "Objective: To evaluate the efficacy of a brief cognitive-behavioral therapy (CBT) that is being developed for management of cognitive dysfunction following chemotherapy among breast cancer survivors. Memory and Attention Adaptation Training (MAAT) is a brief CBT designed to improve the quality of life and function among cancer survivors with post-chemotherapy cognitive complaints. Methods: An initial, two-group (MAAT versus waitlist, no treatment control), randomized clinical trial (RCT) was conducted. Forty stage I and II female breast cancer survivors (mean age = 50; SD = 6.4) were randomized to conditions and assessed at baseline, post-treatment (8 weeks) and 2-month follow-up assessment points on measures of: (1) self-reported daily cognitive failures; (2) quality of life; and (3) neuropsychological performance. Participants were also assessed for satisfaction with MAAT. Results: With education and IQ as covariates, MAAT participants made significant improvements relative to controls on the spiritual well-being subscale of the quality of life measure and on verbal memory, but statistical significance was not achieved on self-report of daily cognitive complaints. However, moderate-to-large effect sizes were observed on these outcomes. Participants gave MAAT high satisfaction ratings. Conclusions: Although this initial RCT is a small study, MAAT participants appear to improve on one measure of quality of life and verbal memory performance relative to no treatment controls and rate MAAT with high satisfaction. These data are encouraging and support the continued development and evaluation of MAAT efficacy.",
keywords = "breast cancer, chemotherapy, cognitive dysfunction, cognitive-behavioral therapy, survivorship",
author = "Ferguson, {Robert J.} and Brenna McDonald and Rocque, {Michael A.} and Furstenberg, {Charlotte T.} and Susan Horrigan and Ahles, {Tim A.} and Andrew Saykin",
year = "2012",
doi = "10.1002/pon.1878",
language = "English",
volume = "21",
pages = "176--186",
journal = "Psycho-Oncology",
issn = "1057-9249",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Development of CBT for chemotherapy-related cognitive change

T2 - Results of a waitlist control trial

AU - Ferguson, Robert J.

AU - McDonald, Brenna

AU - Rocque, Michael A.

AU - Furstenberg, Charlotte T.

AU - Horrigan, Susan

AU - Ahles, Tim A.

AU - Saykin, Andrew

PY - 2012

Y1 - 2012

N2 - Objective: To evaluate the efficacy of a brief cognitive-behavioral therapy (CBT) that is being developed for management of cognitive dysfunction following chemotherapy among breast cancer survivors. Memory and Attention Adaptation Training (MAAT) is a brief CBT designed to improve the quality of life and function among cancer survivors with post-chemotherapy cognitive complaints. Methods: An initial, two-group (MAAT versus waitlist, no treatment control), randomized clinical trial (RCT) was conducted. Forty stage I and II female breast cancer survivors (mean age = 50; SD = 6.4) were randomized to conditions and assessed at baseline, post-treatment (8 weeks) and 2-month follow-up assessment points on measures of: (1) self-reported daily cognitive failures; (2) quality of life; and (3) neuropsychological performance. Participants were also assessed for satisfaction with MAAT. Results: With education and IQ as covariates, MAAT participants made significant improvements relative to controls on the spiritual well-being subscale of the quality of life measure and on verbal memory, but statistical significance was not achieved on self-report of daily cognitive complaints. However, moderate-to-large effect sizes were observed on these outcomes. Participants gave MAAT high satisfaction ratings. Conclusions: Although this initial RCT is a small study, MAAT participants appear to improve on one measure of quality of life and verbal memory performance relative to no treatment controls and rate MAAT with high satisfaction. These data are encouraging and support the continued development and evaluation of MAAT efficacy.

AB - Objective: To evaluate the efficacy of a brief cognitive-behavioral therapy (CBT) that is being developed for management of cognitive dysfunction following chemotherapy among breast cancer survivors. Memory and Attention Adaptation Training (MAAT) is a brief CBT designed to improve the quality of life and function among cancer survivors with post-chemotherapy cognitive complaints. Methods: An initial, two-group (MAAT versus waitlist, no treatment control), randomized clinical trial (RCT) was conducted. Forty stage I and II female breast cancer survivors (mean age = 50; SD = 6.4) were randomized to conditions and assessed at baseline, post-treatment (8 weeks) and 2-month follow-up assessment points on measures of: (1) self-reported daily cognitive failures; (2) quality of life; and (3) neuropsychological performance. Participants were also assessed for satisfaction with MAAT. Results: With education and IQ as covariates, MAAT participants made significant improvements relative to controls on the spiritual well-being subscale of the quality of life measure and on verbal memory, but statistical significance was not achieved on self-report of daily cognitive complaints. However, moderate-to-large effect sizes were observed on these outcomes. Participants gave MAAT high satisfaction ratings. Conclusions: Although this initial RCT is a small study, MAAT participants appear to improve on one measure of quality of life and verbal memory performance relative to no treatment controls and rate MAAT with high satisfaction. These data are encouraging and support the continued development and evaluation of MAAT efficacy.

KW - breast cancer

KW - chemotherapy

KW - cognitive dysfunction

KW - cognitive-behavioral therapy

KW - survivorship

UR - http://www.scopus.com/inward/record.url?scp=84856245323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856245323&partnerID=8YFLogxK

U2 - 10.1002/pon.1878

DO - 10.1002/pon.1878

M3 - Article

C2 - 22271538

AN - SCOPUS:84856245323

VL - 21

SP - 176

EP - 186

JO - Psycho-Oncology

JF - Psycho-Oncology

SN - 1057-9249

IS - 2

ER -